205 related articles for article (PubMed ID: 32561655)
1. Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Shi CX; Zhu YX; Bruins LA; Bonolo de Campos C; Stewart W; Braggio E; Stewart AK
Mol Cancer Res; 2020 Oct; 18(10):1453-1464. PubMed ID: 32561655
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
[TBL] [Abstract][Full Text] [Related]
3. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
4. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
5. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
6. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
Allmeroth K; Horn M; Kroef V; Miethe S; Müller RU; Denzel MS
Leukemia; 2021 Mar; 35(3):887-892. PubMed ID: 32690882
[No Abstract] [Full Text] [Related]
7. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
[TBL] [Abstract][Full Text] [Related]
8. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
9. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
Vangala JR; Dudem S; Jain N; Kalivendi SV
J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
[TBL] [Abstract][Full Text] [Related]
10. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.
Yuan C; Yuan M; Li W; Cheng H; Luo J; Zhang Q; Shi M; Niu M; Yang J; Sun Z; Yan Z; Xu K; Li Z; Yao Y
Exp Cell Res; 2023 Aug; 429(1):113634. PubMed ID: 37207970
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
12. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
[TBL] [Abstract][Full Text] [Related]
13. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J
Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
[TBL] [Abstract][Full Text] [Related]
15. Identification of proteasome subunit beta type 6 (PSMB6) associated with deltamethrin resistance in mosquitoes by proteomic and bioassay analyses.
Sun L; Ye Y; Sun H; Yu J; Zhang L; Sun Y; Zhang D; Ma L; Shen B; Zhu C
PLoS One; 2013; 8(6):e65859. PubMed ID: 23762443
[TBL] [Abstract][Full Text] [Related]
16. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
17. Structural analysis and chromosomal localization of the mouse Psmb5 gene coding for the constitutively expressed beta-type proteasome subunit.
Kohda K; Matsuda Y; Ishibashi T; Tanaka K; Kasahara M
Immunogenetics; 1997; 47(1):77-87. PubMed ID: 9382924
[TBL] [Abstract][Full Text] [Related]
18. Sequencing of amphioxus PSMB5/8 gene and phylogenetic position of agnathan sequences.
Takezaki N; Zaleska-Rutczynska Z; Figueroa F
Gene; 2002 Jan; 282(1-2):179-87. PubMed ID: 11814690
[TBL] [Abstract][Full Text] [Related]
19. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
Wang L; Kumar S; Fridley BL; Kalari KR; Moon I; Pelleymounter LL; Hildebrandt MA; Batzler A; Eckloff BW; Wieben ED; Greipp PR
Clin Cancer Res; 2008 Jun; 14(11):3503-13. PubMed ID: 18519783
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Immunoproteasome-Specific Proteolytic Activity Using Fluorogenic Peptide Substrates.
Kim S; Park SH; Choi WH; Lee MJ
Immune Netw; 2022 Jun; 22(3):e28. PubMed ID: 35799704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]